Cybin Uses Psychedelic Mushroom Derivative To Tackle Depression With Improved Safety
Emerging Company Profile: Cybin’s novel approach to psilocybin therapeutics aims for better safety, shorter duration and less variability through the process of deuteration.
You may also be interested in...
While more money will be poured into COVID-19 vaccines, the pandemic's effects will be felt on overall growth of global medicine use following disruptions to patient engagement with healthcare, a new report from the IQVIA Institute for Human Data Science predicts.
The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.
The latest drug development news and highlights from our US FDA Performance Tracker.